Abivax (ABVX) Non-Current Assets (2021 - 2026)
Abivax (ABVX) posted quarterly Non-Current Assets of $39.7 million for Q1 2026, up 10.16% year-over-year from $36.1 million in Q1 2025, and up 3.08% quarter-over-quarter from $38.5 million in Q4 2025.
Abivax (ABVX) Non-Current Assets (2021 - 2026) Analysis & Trends
Abivax's Non-Current Assets history runs 6 years deep, the most recent figure standing at $39.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 10.16% year-over-year to $39.7 million; the TTM figure through Mar 2026 stood at $39.7 million (up 10.16% YoY), while the FY2025 annual figure was $38.5 million, up 4.33% from the prior year.
- Non-Current Assets for Q1 2026 stood at $39.7 million, up from $38.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $44.7 million in Q2 2024, with the low at $36.1 million in Q1 2025.
- The 5-year median for Non-Current Assets is $38.5 million (2025), against an average of $39.6 million.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets retreated 16.47% in 2024, then grew 10.16% in 2026.
- Abivax's Non-Current Assets stood at $40.2 million in 2022, then climbed by 10.09% to $44.2 million in 2023, then decreased by 16.47% to $36.9 million in 2024, then increased by 4.33% to $38.5 million in 2025, then climbed by 3.08% to $39.7 million in 2026.
- Business Quant data shows ABVX's Non-Current Assets at $39.7 million in Q1 2026, $38.5 million in Q4 2025, and $38.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 39.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.71 Mn |
| Dec 31, 2025 | 38.53 Mn |
| Sep 30, 2025 | 38.29 Mn |
| Jun 30, 2025 | 37.96 Mn |
| Mar 31, 2025 | 36.05 Mn |
| Dec 31, 2024 | 36.93 Mn |
| Jun 30, 2024 | 44.70 Mn |
| Dec 31, 2023 | 44.21 Mn |
| Dec 31, 2022 | 40.16 Mn |
| Dec 31, 2021 | 38.60 Mn |